The pharmaceutical company, previously headquartered in Birmingham, has secured a $450 million financing agreement to help reduce its dependence on capital markets.
The pharmaceutical company, previously headquartered in Birmingham, has secured a $450 million financing agreement to help reduce its dependence on capital markets.
